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nitrate and iNOS cofactors reflecting elevated NO levels.5 In
addition, drugs that have been shown to limit the growth of
experimental AAA, including propanalol, methylpred-
nisolone, doxycycline, cyclosporine, and cyclooxygenase
inhibitors, are known to suppress NO production.6-11
The current study investigates the effect of NO pro-
duction by iNOS on experimental AAA. Specifically, in
this project we indirectly assessed NO production by
means of plasma nitrite/nitrate levels and iNOS expres-
sion during experimental AAA development. Also, selec-
tive inhibition of iNOS-dependent NO production with
aminoguanidine was evaluated and compared with stan-
dard experimental AAA development.
METHODS
Animal surgery. Adult male Wistar rats (300-400 g)
were subjected to surgery as described by Anidjar et al12
and modified by Bigatel et al.13 The described protocols
were reviewed and approved by the Institutional Animal
Care and Use Committee. The animal care complied with
the Guide for the Care and Use of Laboratory Animals,
Institute of Laboratory Animal Resources, Commission
on Life Sciences, and National Research Council
(National Academy Press, Washington, 1996). Rats were
anesthetized with inhalational isoflurane (1%-2.5%) anes-
thesia. A laparotomy was performed, and a 1-cm segment
of infrarenal aorta was isolated. The vena cava was dis-
Nitric oxide (NO) synthesis is carried out by cells
expressing either endothelial nitric oxide synthase (eNOS)
or inducible nitric oxide synthase (iNOS).1 NO produced
by eNOS in the endothelial cell is frequently cited for its
vasodilating properties and protective role in vascular dis-
ease.2 In contrast, NO produced by iNOS within inflam-
matory cells generates high NO levels and toxic products
known to degrade elastin.3,4
The association of inflammation and abdominal aortic
aneurysms (AAAs) is well documented. However, expres-
sion of iNOS and the role of NO during AAA development
have not been investigated. Indirect evidence suggests NO
may play a role in aneurysm pathogenesis. Kawasaki disease,
noted for its arterial inflammation and coronary artery
aneurysms, is associated with increased urinary nitrite/
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Inhibition of inducible nitric oxide synthase limits
nitric oxide production and experimental
aneurysm expansion
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Purpose: Nitric oxide (NO), frequently cited for its protective role, can also generate toxic metabolites known to degrade
elastin. Both abdominal aortic aneurysms (AAAs) and inducible nitric oxide synthase (iNOS) are associated with
inflammatory states, yet the relationship between NO production by iNOS and AAA development is unknown. The
current study examines iNOS expression, NO production, and the effects of selective inhibition of iNOS by
aminoguanidine in experimental AAA.
Methods: An intra-aortic elastase infusion model was used. Control rats received intra-aortic saline infusion and post-
operative intraperitoneal saline injections (Group 1). In the remaining groups, intra-aortic elastase infusion was used
to induce aneurysm formation. These rats were treated with intraperitoneal injections of saline postoperatively (Group
2), aminoguanidine postoperatively (Group 3), or aminoguanidine preoperatively and postoperatively (Group 4).
Aortic diameter and plasma nitrite/nitrate levels were measured on the day of surgery and postoperative day 7. Aortas
were harvested for biochemical and histologic analysis on postoperative day 7.
Results: Infusion of elastase produced AAAs (P < .001) with significant production of iNOS (P < .05) and
nitrite/nitrate (P < .003) compared with controls. Selective inhibition of iNOS with aminoguanidine in elastase-
infused aortas significantly reduced aneurysm size (P < .01) compared with elastase infusion alone. Aminoguanidine-
treated rats displayed suppression of iNOS expression and plasma nitrite/nitrate production not significantly different
from the control group. Histologic evaluation revealed equivalent inflammatory infiltrates in elastase-infused groups.
Conclusion: Expression of iNOS is induced and plasma nitrite/nitrate levels are increased in experimental AAA.
Inhibition of iNOS limits NO production and iNOS expression, resulting in smaller aneurysm size. NO production by
iNOS plays an important role with detrimental effects during experimental aneurysm development. (J Vasc Surg
2001;33:579-86.)
sected free from the aorta, and all lumbar artery branches
were ligated. With a cutdown on the external iliac artery,
a 24-gauge intravenous catheter (Johnson & Johnson,
Arlington, Tex) was introduced, and blood was collected
for plasma analysis. The catheter was removed and a PE-
10 polyethylene catheter (VWR Scientific Products,
Bridgeport, NJ) was threaded into the aorta until its tip
was resting in the isolated segment. Temporary ligatures
were placed proximally and distally, and the aorta was per-
fused with a solution of saline or elastase dissolved in saline
solution. Two milliliters was infused over 2 hours with a
microinfusion pump (Bioanalytical Systems Inc, W
Lafayette, Ind; Harvard Apparatus, S Natick, Mass). The
laparotomy was closed, and all skin wounds were stapled.
The rats recovered, were individually housed, and given
standard rat chow and water as desired. The animals were
maintained until postoperative day (POD) 7 when they
were anesthetized again. The animals were reexplored via
a standard laparotomy incision, and plasma was collected
through a contralateral iliac artery cutdown. Aortic diam-
eter was measured, the aorta was harvested, and each rat
was euthanized.
Aortic infusion and drug administration. Rats in
Groups 1, 2, and 3 were randomized to aortic infusion
and drug administration. Group 1 served as a control
group, receiving intra-aortic saline infusion and postoper-
ative saline. The remaining rats received an intra-aortic
infusion of 12 units of elastase (Product #E-1250, Lots
18H7440 and 79H7628, unit activity determined by
Succinyl-Ala-Ala-Ala-p-nitroanalide as substrate; Sigma, St
Louis, Mo) mixed in 2 mL of saline. Each rat received a 1-
mL intraperitoneal injection of saline (Group 2) or
aminoguanidine (200 mg/kg) (Group 3) beginning on
the morning of POD 1 and continuing through POD 7.
A fourth group of rats underwent operation without ran-
domization to assess the effect of preoperative and post-
operative administration of aminoguanidine. These rats
received intra-aortic elastase infusion identical to Groups 2
and 3 but received aminoguanidine starting 5 days preop-
eratively and continuing through POD 7. The dose of
aminoguanidine was chosen on the basis of previous stud-
ies in animal models where inflammation was a prominent
component and an intraperitoneal injection was used.14,15
Aortic measurement and tissue preparation. All
aortas were measured with pulsatile blood flow before and
after infusion of intra-aortic solutions and at the time of
reexploration. Aortic diameter was measured in situ under
physiologic conditions with an ocular micrometer with
0.1-mm graduations at 10× power. At harvest, the infused
segment of aorta was removed and divided into two equal
pieces. The sections were snap frozen in liquid nitrogen
for biochemical analysis and fixed in formaldehyde for his-
tologic evaluation.
Biochemical and histologic analysis. Aortic tissue
was analyzed with immunocytochemistry and Western
blot analysis to assess iNOS expression and localization.
Western blots were prepared as follows: Frozen aortic
samples were homogenized in 5 mol/L urea, 50 mmol/L
Tris, and 25 mmol/L dithiothreitol, pH 7.4 for equivalent
sample concentrations (weight/volume). The samples
were then mixed with electrophoresis gel sample buffer,
heated, and loaded onto 7.5% sodium dodecylsulphate–
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Fig 1. Infusion of elastase created a significant increase in aortic diameter in all groups when compared with saline infusion. Aortic diame-
ter increased more than 400% in rats with elastase infusion and saline injections. iNOS inhibition with postoperative aminoguanidine
resulted in 28% reduction in aneurysm size. Preoperative aminoguanidine administration produced further significant reduction in aortic
diameter with 48% decrease in aortic diameter. POD, Postoperative day; Post Op, postoperative; Pre Op, preoperative; *P < .01; **P < .001.
polyacrylamide gels. The gels were run until the dye front
approached the gel edge, and then the proteins were
transferred to polyvinylidene difluoride (PVDF) mem-
brane (Immobilon-P). Membranes were stained with
Ponceau to ensure adequate and equivalent protein load-
ing onto the PVDF membrane. The membrane was
blocked with 2% nonfat powdered milk and then incu-
bated with anti-iNOS antibody (Transduction Labora-
tories, Lexington, Ky; 1:2500). The membrane was rinsed
and incubated with horseradish peroxidase–conjugated
secondary antibody. Enhanced chemiluminescence was
used to detect iNOS expression, and arbitrary light units
(ALUs) were measured to quantify protein levels.
Chemiluminescence detection was performed with a digi-
tal camera with broad dynamic range (Lumimager; Roche
Molecular Biochemicals, Indianapolis, Ind), and Western
blot analysis was consistent across multiple blots.
Immunocytochemistry was performed for iNOS and
inflammatory cell localization. Aortic tissue was frozen in
Tissue-Tek O.C.T. Compound (Miles, Inc, Elkhart, Ind)
and sectioned at a thickness of 8 µm. After blocking, the
specimens were incubated with anti-iNOS (Transduction
Laboratories; 1:200) and MAC-1 antibody (Seikagaku
Corp, Tokyo, Japan; 1:100). Fluorescein isothiocyanate
and Texas Red conjugated secondary antibodies were used
for immunofluorescence. The slides were viewed with a
Zeiss fluorescent microscope (Zeiss, Inc, Thornwood,
NJ), and images were acquired with a digital camera.
Formalin-fixed specimens were processed for hema-
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toxylin and eosin and orcein-elastin staining. Inflammation
was graded with paraffin-embedded aortic sections stained
with hematoxylin and eosin under light microscopy. A
scoring system was developed to allow for quantitation of
the findings. The levels of inflammation were assigned as
follows: 5 = severe inflammation, 4 = moderate to severe
inflammation, 3 = moderate inflammation, 2 = minimal to
moderate inflammation, and 1 = minimal inflammation.
Grading of the specimens was performed in a blinded fash-
ion. Elastin-stained sections were evaluated for qualitative
changes in elastin loss.
Plasma analysis. Blood (500 µL) was collected at the
time of the initial laparotomy and at the time of harvest in
EDTA-containing microtainers (Becton Dickinson,
Franklin Lakes, NJ). The blood specimens were cen-
trifuged for 10 minutes at 3000 rpm, and the plasma was
decanted for further analysis. NO levels were indirectly
quantitated by measuring total nitrite and nitrate levels in
50-µL samples with the Griess reaction. The assay sensi-
tivity for plasma nitrite/nitrate was 0.6 to 0.9 µmol/L,
and the reproducibility of the assay was ± 9% (assay per-
formed by Oxonon, Inc, Emeryville, Calif).
Statistics. Comparisons of aortic diameter between
the groups and absolute plasma nitrite/nitrate levels
between the groups at the time of operation and on POD
7 were assessed with one-way analysis of variance
(ANOVA) with Bonferrini correction. Comparing plasma
nitrite/nitrate levels at the time of operation with POD 7
within each group was performed with a paired sample t
Fig 2. Plasma samples were analyzed with Griess reaction to determine changes in NO levels from time of operation to POD 7. There
was no change in plasma nitrite/nitrate levels for saline-infused rats. Infusion of elastase produced significant increase in plasma
nitrite/nitrate levels on POD 7 for rats injected with saline but not in rats treated with aminoguanidine (AG) Post-Op, Postoperative;
Pre-Op, preoperative; *P < .003.
test. Comparison of iNOS expression between the groups
and the severity of inflammation between the groups were
calculated with the Kruskal-Wallis rank sum test. Mortality
rates were compared with the Fisher exact test. Data are
reported as mean ± SD. The INSTAT statistical program
(GraphPAD Software; Prism Inc, San Diego, Calif) and
SAS statistical software package (SAS Institute, Inc, Cary,
NC) were used for statistical calculations.
RESULTS
In each group, eight rats were evaluated. There was no
significant change in aortic diameter in rats receiving intra-
aortic saline infusion (Group 1) when comparing postin-
fusion with harvest diameter (Fig 1). In contrast,
intra-aortic elastase infusion produced aneurysms in
Groups 2, 3, and 4 (Group 1, 2.0 ± 0.3 mm vs Group 2,
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Fig 3. Sixteen aortic specimens, four from each group, were analyzed with Western blot for expression of iNOS. Specimens from Group
1 (intra-aortic saline) demonstrated absence of iNOS expression, with specimens from Group 2 (intra-aortic elastase) demonstrating
iNOS expression in three of four samples. Treatment with aminoguanidine resulted in significant reduction of iNOS expression, with
presence of iNOS noted in one of four samples in postoperatively treated (Group 3) rats and with absence of iNOS expression in those
treated preoperatively (Group 4) (P < .05).
Fig 4. For localization of iNOS expression, aortic cross sections were stained with anti-iNOS and MAC-1 antibody specific for in-
flammatory cells. At 25× magnification, MAC-1 staining demonstrates significant inflammatory infiltrate within adventitia. iNOS co-
localizes with inflammatory infiltrate within adventitia. iNOS, Inducible nitric oxide synthase; A, adventitia; L, lumen; M, media.
8.7 ± 1.2 mm, P < .001; Group 1 vs Group 3, 6.4 ± 1.2
mm, P < .001; Group 1 vs Group 4, 4.5 ± 0.7 mm, P <
.001). There was a significant reduction in aortic diameter
for rats receiving aminoguanidine compared with Group 2
rats receiving saline (Group 2 vs Group 3, P < .01; Group
2 vs Group 4, P < .001). The addition of preoperative
aminoguanidine administration resulted in significant
reduction of aortic diameter (Group 3 vs Group 4; P <
.01) compared with postoperative administration alone.
There were six aortic ruptures in both Group 2 and Group
3 and no aortic ruptures in Group 1 (P < .05). Group 4
had two aortic ruptures that were not significantly differ-
ent compared with Groups 1, 2, and 3.
Measurement of plasma nitrite/nitrate levels with the
Griess reaction demonstrated a significant increase in
nitrite/nitrate levels (P < .003) for rats receiving intra-aor-
tic elastase and saline injections (Group 2) on POD 7
(24.4 ± 6.6 µmol/L) compared with the day of operation
(18.2 ± 7.5 µmol/L). No significant increase in nitrite/
nitrate levels were noted with intra-aortic saline infusion
or with aminoguanidine treatment (Fig 2). ANOVA analy-
sis between groups demonstrated no significant difference
in absolute plasma nitrite/nitrate levels at the time of
operation and at the time of harvest.
Sixteen aortic specimens, four from each group, were
analyzed with Western blot analysis for expression of iNOS
(Fig 3). Specimens from Group 1 (intra-aortic saline)
demonstrated absence of iNOS expression (ALU = 0),
with specimens from Group 2 (intra-aortic elastase)
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demonstrating iNOS expression in three of four samples
(mean ALU = 4.3 × 105). Treatment with aminoguanidine
resulted in a significant reduction of iNOS expression,
with the presence of iNOS noted in one of four samples in
postoperatively treated (Group 3; mean ALU = 5 × 104)
rats and with the absence of iNOS expression in those
treated preoperatively (Group 4, ALU = 0) (P < .05).
Localization of iNOS with the use of immunocyto-
chemistry demonstrated presence of the enzyme through-
out all layers of the arterial wall, with most localized to the
adventitia (Fig 4). Macrophage staining with MAC-1 anti-
body demonstrated localization of the macrophages and
other inflammatory cells within the adventitia of the arte-
rial wall. There was noted to be co-localization of iNOS
and macrophage staining at high power; however, multi-
ple cells other than macrophages were noted to be positive
for iNOS staining (Fig 5). In addition, there was localiza-
tion of iNOS within the arterial medial layer where
macrophage staining was conspicuously absent (Fig 6).
Infusion of saline (Group 1) resulted in retention of
elastin fibers in the medial layer and minimal thickening
and disruption of the adventitia. For all rats receiving elas-
tase (Groups 2, 3, and 4), there was virtually complete loss
of elastin within the medial layer and a thickened adventi-
tia consisting of a dense inflammatory infiltrate.
Treatment with aminoguanidine (Group 3, median = 5;
Group 4, median = 4.5) resulted in no significant decrease
in the severity of inflammation compared with Group 2
(median = 5) (Fig 7).
Fig 5. For localization of iNOS and inflammatory cells within adventitia, tissue sections were dual stained with anti-iNOS and MAC-1
antibodies and photographed with a digital camera at a final magnification of 100×. Digital images were pseudocolored and superim-
posed. Areas of yellow demonstrate overlap of iNOS and inflammatory cells. There is co-localization of iNOS and inflammatory cells
(small arrows) and areas of iNOS staining where MAC-1 is absent (large arrows). iNOS, Inducible nitric oxide synthase.
DISCUSSION
The current study documents elevated plasma nitrite/
nitrate levels in experimental aneurysms correlating with
expression of iNOS. Selective blockade of NO production
by the inhibitor aminoguanidine resulted in a significant
reduction in experimental aneurysm size when given post-
operatively. A further significant reduction in aneurysm size
was noted with the addition of preoperative aminoguanidine
compared with postoperative administration alone. The
expression of iNOS was found throughout the arterial wall
but localized predominantly to the inflammatory infiltrate.
However, presence of iNOS within the media and its local-
ization in the adventitia separate from macrophages suggest
iNOS may be produced by smooth muscle cells and fibro-
blasts. The time course of iNOS induction was not directly
studied; however, the significant decrease in aortic diameter
with the addition of preoperative aminoguanidine suggests
iNOS is induced early in aneurysm formation. These find-
ings indicate that iNOS is induced and expressed early in the
sequence of experimental aneurysm formation by multiple
cells, leading to elevated NO levels whose effects are delete-
rious to the aorta.
Until now, only indirect evidence linked NO with
aneurysm formation. In human aortic aneurysms, nitrite
levels are sevenfold greater than in normal aortas,16 and at
this physiologic concentration nitrite in vitro will degrade
elastin.4 Kawasaki disease, a vascular inflammatory disease
of childhood characterized by coronary artery aneurysms,
has been associated with increased urinary nitrite/nitrate
and iNOS cofactors consistent with increased NO levels.
In addition, the severity and course of the disease corre-
lated with levels of nitrite/nitrate.5 The current study doc-
uments a significant increase in nitrite/nitrate levels
associated with experimental AAA.
A common mechanism of action in many drugs that
limit aneurysm growth in the current model of experi-
mental AAA is their ability to suppress NO production.
This includes the β-blocker propanolol, the anti-inflam-
matory drugs methylprednisolone and cyclosporine, the
antibiotic and matrix metalloproteinase (MMP) inhibitor
doxycycline, and the cyclooxygenase inhibitor lornoxi-
cam.6-11 The fact that aminoguanidine, a selective iNOS
inhibitor, limited aneurysm growth to the same or greater
extent as many of the above-named drugs suggests that a
common mechanism of action is NO suppression.
Whether the mechanism of action of these drugs is related
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Fig 6. For localization of iNOS and inflammatory cells within media, tissue sections were stained with anti-iNOS and MAC-1 antibod-
ies at 50× magnification and photographed. iNOS is present within medial layer (M) where MAC-1 staining is conspicuously absent.
Thus, immunocytochemistry suggests iNOS is produced not only by macrophage/monocyte cell line, but possibly by smooth muscle
cells and fibroblasts. iNOS, Inducible nitric oxide synthase.
to NO suppression, their known primary effects, or both
remains to be seen.
Aminoguanidine in vitro and in vivo selectively
inhibits the activity of iNOS and is 10 to 250 times more
selective for iNOS than eNOS.17,18 Aminoguanidine’s
ability to inhibit eNOS in vivo at the current dosage is
unknown, and blood pressure was not recorded during
this experiment. However, others have shown blood pres-
sure in anesthetized Sprague Dawley rats to significantly
increase with the administration of aminoguanidine at a
dose of 60 mg/kg.19 If aminoguanidine were to increase
blood pressure at the dosage used in our study, one would
expect an increase in aneurysm size and expansion rate.
Thus, paradoxically, aminoguanidine may increase blood
pressure while limiting aneurysm expansion. Another
interesting finding is the decreased expression of iNOS
with the administration of aminoguanidine. Amino-
guanidine has been shown by other investigators to
decrease iNOS expression in a dose-dependent fashion in
vivo consistent with the current study.20 The mechanism
of action for this finding is currently unknown.
Inflammation with a macrophage infiltrate is a consis-
tent feature of experimental AAA.21 In addition,
macrophages have been found to be the predominant
source of NO production by iNOS.1 The current study
supports iNOS as the source of NO in experimental AAA.
With immunocytochemistry, macrophages were shown to
co-localize with iNOS; however, multiple cells stained
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positively for iNOS within the inflammatory cell deficient
medial layer. This finding is consistent with studies
demonstrating that iNOS can be expressed in smooth
muscle and endothelial cells.1 The presence of iNOS
throughout the arterial wall and the inflammatory infil-
trate suggests that multiple cell types in experimental AAA
regulate NO production. Aminoguanidine did not
decrease the severity of inflammation while limiting
aneurysm expansion.
MMPs are elevated in AAA and associated with extra-
cellular matrix degradation. Our laboratory,13 as well as
other investigators,22 has shown that blockade of these
MMPs limits aneurysm expansion. This suggests that NO
may play a role in MMP regulation. Several studies exist to
document the role of NO in MMP regulation. NO pro-
duced by eNOS gene transfer has been shown to inhibit
smooth muscle cell migration and MMP-2 and MMP-9
activity in cultured rat vascular smooth muscle cells.23 In
contrast, peroxynitrite, a reactive metabolite produced by
NO and a superoxide anion, has been shown to nitrate
MMP-2, resulting in collagenolytic activity.24 Other stud-
ies have documented a tonic inhibition of MMP-9 by
NO.25 The current available research on NO and its rela-
tionship to MMPs suggests NO may play a role in the reg-
ulation of MMPs in AAA development.
The mechanism of action by which NO exerts its
effects in experimental aneurysm formation is currently
unknown. NO produced by eNOS and iNOS can act indi-
Fig 7. Paraffin sections of aortas were stained with elastin-orcein and photographed at final magnification of 50×. In saline-infused rats,
there was retention of elastin fibers in medial layer and minimal thickening and disruption of adventitia (a). For all rats receiving elastase,
there was virtually complete loss of elastin within medial layer and thickened adventitia containing dense inflammatory infiltrate (b, c, d).
Treatment with aminoguanidine resulted in no significant decrease in inflammatory response (c, d). A, Adventitia; M, medial layer.
rectly through MMP regulation and as a cellular messen-
ger through cyclic guanosine monophosphate activation.1
Considering direct effects, iNOS produces NO at a rate
1000-fold greater than eNOS. This, coupled with the
knowledge that aminoguanidine blockade of iNOS signif-
icantly reduced aneurysm size, suggests high levels of NO
are detrimental to the arterial wall. High levels of NO are
associated with the production of peroxynitrite that can be
directly toxic to cells through oxidative mechanisms. In
addition, increased NO, peroxynitrite, and superoxide dis-
mutase can act in combination to nitrate tyrosine amino
acids. The resulting nitrotyrosine can significantly impair
cytoskeletal proteins that participate in extracellular matrix
remodeling.3 Current literature suggests multiple avenues
exist by which NO could affect aneurysm development.
CONCLUSION
These results document that increased plasma
nitrite/nitrate levels and expression of iNOS occur at sites
of aneurysm development. iNOS is expressed early in
experimental aneurysm formation by multiple cells, lead-
ing to elevated NO levels, whose effects are deleterious to
the aorta. Inhibition of iNOS-dependent NO production
by aminoguanidine resulted in decreased plasma
nitrite/nitrate levels and iNOS expression, with a signifi-
cant limitation of aneurysmal expansion.
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